Real-World Survival Outcomes in Patients with Different Types of Cancer Managed with Immune Checkpoint Inhibitors
Satisfactory survival was observed in this elderly patient cohort, but survival varied with tumor type and performance status. Age was not a major determinant of survival. However, the oldest patients were at higher risk of short survival.
Authors
- Bård Mannsåker (ORCID: https://orcid.org/0009-0007-6730-5473)
- Ellinor Haukland (ORCID: https://orcid.org/0000-0002-5697-2218)
- Carsten Nieder (ORCID: https://orcid.org/0000-0003-1592-2908)
- Luka Stanisavljević
- Siv Gyda Aanes (ORCID: https://orcid.org/0009-0000-0593-0248)
Institutions
- Nordland Hospital Trust (NO)
- UiT The Arctic University of Norway (NO)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1159/000542958
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57